Medpace Holdings, Inc. (MEDP) on Decifer

Decifer ranks MEDP number 87 of 268 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 20% a year, faster than 68 in 100 companies we measure.
• It keeps about 27 cents of every sales dollar as cash, safer than 90 in 100 companies we measure.
• It earns about 70% a year on the money put into the business, better than 99 in 100 companies we measure.
• It costs about 37 times its yearly profit; the middle of its industry is 37. Cheaper than 48 in 100 companies we measure, against their own industries.

The current read

The evidence on MEDP lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Pharma Innovation Financing & Outsourced R&D: Rising cost and complexity of clinical development is pushing biopharma toward outsourced trial execution and non-dilutive royalty capital.

Read the full MEDP research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.